ESC Congress 2014 focuses on innovations in cardiology

PUBLIC RELEASE DATE:

28-Jul-2014

Contact: ESC Press Office press@escardio.org 33-049-294-8627 European Society of Cardiology

Sophia Antipolis, 28 July 2014: ESC Congress 2014 promises to be bigger, better and more interactive than ever before, says Professor Keith Fox, Chair of the Congress Programme Committee. The European Society of Cardiology hosts the world's largest and most influential cardiovascular event every year in August. Record numbers of Hot Line sessions and abstracts were submitted this year and the congress is on track to host the largest number of delegates in its history.

Asked why an extra hot line session has been added this year, with 27 presentations in total, Professor Fox said: "We have an abundance of riches, with an all time high of 247 hot line and clinical trial update submissions. These hot lines are embargoed, and many will appear in the major journals so I can't talk about any results. But I know just from the topics that there is a huge amount of interest."

PARADIGM-HF kicks off the hot line sessions by comparing the impact of gold standard treatment with an ACE inhibitor to a new angiotensin receptor blocker-neprilysin inhibitor (ARNI) on mortality and morbidity. The trial was stopped early for a benefit to patients that was overwhelmingly statistically significant and the results will be revealed for the first time at ESC Congress.

The results of other major trials are eagerly anticipated (see schedule here), such as the SOLID-TIMI 52 trial of the PLA2 inhibitor darapladib. Previous studies have reported its effects in stable coronary artery disease but this is the first trial in myocardial infarction.

Innovative treatment approaches featured in the hot lines include vagal stimulation for systolic heart failure (NECTAR-HF), nitric oxide inhalation to reduce reperfusion injury in STEMI (NOMI) and the novel anti-Xa rivaroxaban for cardioversion (X-VERT).

Professor Fox said: "Several of these trials are really going to change clinical practice and our approaches to managing patients. There will also be a number of important clinical trial updates and big registries that are also going to influence practice."

In addition to the 20 registry Hot Lines and 15 clinical trial update, 11 basic and translational science hot lines were chosen from 80 submissions.

See the original post here:
ESC Congress 2014 focuses on innovations in cardiology